iShares Biotechnology ETF
866 hedge funds and large institutions have $5.2B invested in iShares Biotechnology ETF in 2023 Q4 according to their latest regulatory filings, with 122 funds opening new positions, 177 increasing their positions, 373 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
2.23% more ownership
Funds ownership: 66.98% → 69.21% (+2.2%)
53% less repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 373
75% less call options, than puts
Call options by funds: $353M | Put options by funds: $1.42B
Holders
866
Holding in Top 10
10
Calls
$353M
Puts
$1.42B
Top Buyers
| 1 | +$300M | |
| 2 | +$74.1M | |
| 3 | +$29.6M | |
| 4 |
JP Morgan Chase
New York
|
+$25.1M |
| 5 |
JHU
Johns Hopkins University
Baltimore,
Maryland
|
+$21.9M |
Top Sellers
| 1 | -$170M | |
| 2 | -$44.2M | |
| 3 | -$40.9M | |
| 4 |
Goldman Sachs
New York
|
-$33M |
| 5 |
Jane Street
New York
|
-$26.4M |